The Largest Companies in Major Pharmaceutical Preparations Industry Value and Market Capitalization, Revenue, Income, Number of Employees - CSIMarket
Healthcare Sector

The Largest Companies in Major Pharmaceutical Preparations Industry

Explore the largest companies by market capitalization, revenue, income, and employees within the Major Pharmaceutical Preparations industry

Classification: SIC NAICS ISIC Available under Commercial License
TTM data as of: September 29, 2026
Total Market Cap
$ 6,904B
Billions USD (aggregate)
Total Revenue (TTM)
$ 1,222B
Trailing twelve months
Total Net Income (TTM)
$ 194B
Trailing twelve months
Total Employees
1,144,211
Headcount (aggregate)
API endpoints for this dataset
https://api.csimarket.com/api/v1/industries/803/list
Programmatic access for models, analytics, and integration workflows.

Explore the largest companies by market capitalization, revenue, income, and employees within the Major Pharmaceutical Preparations industry

Company Market Cap
(Millions)
Revenue TTM
(Millions)
Net Income TTM
(Millions)
Employees
Total Major Pharmaceutical Preparations Industry $ 6,904,071 $ 1,222,257 $ 193,800 1,144,211
646 more companies available

Sign in to unlock the full Major Pharmaceutical Preparations Industry dataset.

Industry Benchmarking Dataset for Institutional Use

Commercial

The data presented above is part of our institutional-grade Industry Benchmarking Dataset, designed for integration into credit risk models, AML/KYC frameworks, portfolio analytics, and internal banking systems. The full dataset is available under a Commercial License, with delivery via API or bulk CSV datasets.

Advanced Metrics & Analytics
  • Multi-year CAGRs & growth acceleration signals
  • Volatility measures & trend stability indicators
  • Cross-sectional percentiles (median, p25, p75)
  • Dispersion metrics (std deviation, spread)
  • Composite scores (growth quality, distress risk)
Institutional Use Cases
  • Credit underwriting & peer benchmarking
  • AML / KYC financial validation
  • Portfolio monitoring & risk tracking
  • Quantitative modeling & factor construction
  • Sector risk & supply chain exposure analysis
Data Delivery
API Access
Real-time endpoints delivering data into risk engines, models, and internal systems.
Bulk CSV Datasets
Pre-structured datasets optimized for direct ingestion into data warehouses, enabling large-scale modeling, backtesting, and historical analysis.
Licensing
Available under institution-grade licensing frameworks with defined usage rights, distribution scope, and integration permissions, supporting internal use, client reporting, and enterprise-wide deployment.
CSIMarket - Industry Benchmarking Data - Per Industry

Institutional-grade industry datasets
in standardized CSV format

Pre-cleaned, audit-ready benchmarking data for this industry - 6 CSV files covering profitability, growth, valuation, efficiency, management effectiveness, and financial strength. Each file delivers 20 quarters and 5 fiscal years of history, with statistical distributions and composite scores per period.

6CSV files
3,880Quarterly endpoints
360Annual endpoints
20Quarters of history
5Fiscal years
Profitability
37 quarterly - 10 annual indicators 790 endpoints ?
Growth
31 quarterly - 7 annual indicators 1,455 endpoints ?
Valuation
29 quarterly - 10 annual indicators 630 endpoints ?
Efficiency
16 quarterly - 12 annual indicators 380 endpoints ?
Management
20 quarterly - 16 annual indicators 480 endpoints ?
Fin. Strength
21 quarterly - 17 annual indicators 505 endpoints ?
Total dataset size - across 110 industries
Quarterly data points
388,000
3,880 × 110 industries
Annual data points
36,000
360 × 110 industries
Industries covered
110
all sectors
Total data points
424,000
quarterly + annual
Industry classification systems supported
CSIMarket Proprietary classification optimized for financial benchmarking and industry analytics
NAICS North American Industry Classification System - used by U.S., Canada & Mexico federal agencies
SIC Standard Industrial Classification - legacy system used by the SEC and financial regulators
ISIC International Standard Industrial Classification - UN framework for global economic comparison
Dataset 1 - Profitability Benchmarks

Margin benchmarks across the full industry distribution

Gross, operating, EBITDA, pre-tax, net, and free cash flow margins - delivered as TTM, quarterly, and annual series with P25 / median / P75 / standard deviation for every reporting period.

Net margin (TTM Q4)
7.44%
+2.11pp vs prior yr
Gross margin
10.44%
industry avg
FCF margin
13.66%
strong
Companies reported
31
Q4 2025
Data coverage per industry
Quarterly indicators
37
metrics per period
Annual indicators
10
fiscal year metrics
Quarterly endpoints
740
20 quarters × 37
Annual endpoints
50
5 fiscal years × 10
Gross, operating, EBITDA, net & FCF margins
TTM, quarterly & fiscal year series
P25 / median / P75 / std dev per period
YoY margin change & acceleration
Effective tax rate & pre-tax margin
Profitability composite score (0–100)
Report preview - Profitability Benchmarks - Aerospace & Defense
Profitability Benchmarks report sample
Dataset 2 - Growth Dynamics

Revenue, income & cash flow growth across 13+ line items

Industry-level growth benchmarks for every major P&L and cash flow line - with breadth indicators showing what share of companies posted positive growth, acceleration metrics, and rolling TTM comparisons.

Revenue growth (TTM Q4)
12.84%
improving
Net income growth
18.45%
above revenue
FCF growth
13.60%
strong
EPS acceleration
+3.69pp
vs prior TTM
Data coverage per industry
Quarterly indicators
31
metrics per period
Annual indicators
7
fiscal year metrics
Quarterly endpoints
1,420
20 quarters × 31
Annual endpoints
35
5 fiscal years × 7
Revenue, gross, EBIT & operating income growth
Net income, EPS (basic & diluted) growth
FCF, net cash flow & CapEx growth
Breadth: % of companies with positive growth
QoQ, YoY, TTM & 3-year CAGR
Growth composite score (0–100)
Report preview - Growth Dynamics - Aerospace & Defense
Growth Dynamics report sample
Dataset 3 - Valuation Multiples

Industry valuation multiples with 5-year context & Z-scores

P/E, P/S, P/FCF, P/Book, EV/EBITDA - current and trailing - with five-year averages, percentile ranks, Z-scores, and a composite valuation score to place the industry in historical context.

P/E ratio (current)
22.4x
vs 5yr avg 14.2x
EV/EBITDA (TTM)
13.1x
P25–P75: 4.5x–20.4x
Earnings yield
4.46%
attractive
Composite val. score
61.7
moderately valued
Data coverage per industry
Quarterly indicators
29
metrics per period
Annual indicators
10
fiscal year metrics
Quarterly endpoints
580
20 quarters × 29
Annual endpoints
50
5 fiscal years × 10
P/E, P/S, P/CF, P/FCF, P/Book multiples
EV/EBITDA & EV/Sales (current & TTM)
5-year historical average per multiple
Z-scores & percentile ranks
Earnings yield & FCF yield
Composite valuation score (0–100)
Report preview - Valuation Multiples - Aerospace & Defense
Valuation Multiples report sample
Dataset 4 - Operational Efficiency

Productivity, turnover ratios & cash conversion benchmarks

Revenue and income per employee, asset and receivables turnover, days sales outstanding, days inventory, days payables, and the full cash conversion cycle - benchmarked across the industry distribution.

Revenue / employee
$487K
improving
Asset turnover
0.61x
P75: 0.80x
Cash conv. cycle
113 days
above avg
Efficiency score
68.7
composite 0–100
Data coverage per industry
Quarterly indicators
16
metrics per period
Annual indicators
12
fiscal year metrics
Quarterly endpoints
320
20 quarters × 16
Annual endpoints
60
5 fiscal years × 12
Revenue & net income per employee
Asset, receivables & inventory turnover
DSO, DIO, DPO & cash conversion cycle
Working capital per revenue
YoY & TTM trend for all metrics
Efficiency composite score (0–100)
Report preview - Operational Efficiency - Aerospace & Defense
Operational Efficiency report sample
Dataset 5 - Management Effectiveness

ROA, ROE, ROIC & DuPont decomposition benchmarks

Return metrics measuring how effectively management allocates capital - with incremental ROIC, DuPont decomposition, FCF quality indicators, and a composite management effectiveness score across the industry.

Return on assets
5.05%
vs 4.44% prior
Return on equity
14.22%
improving
ROIC (TTM)
9.77%
P75: 12.4%
Effectiveness score
72.4
composite index
Data coverage per industry
Quarterly indicators
20
metrics per period
Annual indicators
16
fiscal year metrics
Quarterly endpoints
400
20 quarters × 20
Annual endpoints
80
5 fiscal years × 16
ROA, ROE & ROIC - TTM & quarterly
Incremental ROIC & capital intensity
DuPont 3-factor decomposition
FCF conversion quality metrics
P25 / median / P75 / std dev per metric
Management effectiveness composite (0–100)
Report preview - Management Effectiveness - Aerospace & Defense
Management Effectiveness report sample
Dataset 6 - Financial Strength

Leverage, liquidity & debt coverage across the industry

Debt-to-equity, interest and debt coverage, quick ratio, working capital, leverage ratios - full distribution statistics - in standardized, audit-ready format suited for credit workflows, compliance, and ESG reporting.

Debt / equity (TTM)
1.44x
above industry avg
Interest coverage
8.32x
comfortable
Quick ratio
0.91x
vs P75 1.18x
Fin. strength score
58.4
composite 0–100
Data coverage per industry
Quarterly indicators
21
metrics per period
Annual indicators
17
fiscal year metrics
Quarterly endpoints
420
20 quarters × 21
Annual endpoints
85
5 fiscal years × 17
Quick ratio & working capital ratio
Total & LT debt-to-equity
Leverage & tangible leverage ratios
Interest & debt coverage ratios
P25 / median / P75 / std dev per metric
Financial strength composite score (0–100)
Report preview - Financial Strength - Aerospace & Defense
Financial Strength report sample
Methodology
1. Data Coverage & Universe
Structured dataset built from publicly listed companies, classified across industries, sectors, and total market using CSIMarket, NAICS, SIC, and ISIC frameworks.

Includes up to 5 years of quarterly data (TTM, quarterly, annualized) with continuous updates during earnings cycles.

Coverage transparency includes total companies, reported companies per metric, and coverage ratios.
2. Aggregation Methodology
Industry metrics are calculated using aggregated financial statements, not averages.

Sum-based aggregation is applied to revenue, income, assets, and debt, with market-cap weighting for valuation metrics and TTM normalization to reduce seasonality.

Example: P/E = Total Market Cap ÷ Total Net Income.
3. Ratio Construction
Ratios are standardized and calculated at the company level, then benchmarked across industries.

Covers profitability, valuation, financial strength, efficiency, and growth metrics including margins, ROE, EV multiples, leverage ratios, and CAGR growth measures.
4. Distribution Analytics
Full cross-sectional distribution analysis includes median (P50), quartiles (P25/P75), standard deviation, and interquartile range.

Enables detection of outliers, dispersion, and structural differences within industries.
5. Percentile Rankings
Metrics are normalized into 0–100 percentile rankings using cross-industry PERCENT_RANK().

Direction is adjusted by metric (higher = better for growth/profitability, lower = better for leverage/risk).

Used for benchmarking, factor models, and relative analysis.
6. Volatility & Trend Metrics
Includes volatility (e.g., 8-quarter standard deviation), trend slopes, and growth consistency metrics.

Captures earnings stability, margin durability, and cyclicality across industries.
7. Composite Scores
Multi-factor composite scores (0-100 scale) combine normalized inputs using weighted models.

Includes valuation, growth quality, financial strength, and distress risk scores.
8. Data Quality Controls
Data undergoes standardization, outlier detection, consistency checks, and coverage-based filtering.

Reporting counts and coverage ratios are provided for transparency.
9. Update Frequency
Dataset is continuously updated during earnings seasons.

TTM metrics are recalculated with each new filing, reflecting the most recent reported data.
10. Use Cases
Designed for credit risk analysis, AML/KYC validation, portfolio monitoring, quantitative modeling, and benchmarking workflows.
11. Licensing & Access
Free preview available for evaluation. Full dataset access requires a commercial license.

API and bulk delivery options available for system integration.

Recent News from The Largest Companies in Major Pharmaceutical Preparations Industry

Announcement
Navigating the Challenges and Opportunities A Closer Look at Cytokinetics, Inc. Amid Shareholder Investigations

As the landscape of investment continues to shift, long-term shareholders of Cytokinetics, Inc. (NASDAQ: CYTK) and three other notable companies find themselves amid scrutiny that can potentially reshape their portfolios. Grabar Law Office, a firm known for its shareholder advocacy, has made an important announcement concerning ongoing investigations into...

Nov 27, 2025 • Major Pharmaceutical Preparations Industry
CYTK
Product Service News
Pacira BioSciences Initiates Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical, Enforci...

Pacira BioSciences, Inc. (Nasdaq: PCRX), a prominent biopharmaceutical company recognized for its dedication to developing innovative non-opioid pain management therapies, has taken legal action to protect its proprietary technology. On November 26, 2025, the company announced it had filed a patent infringement lawsuit in the United States District Court ...

Nov 27, 2025 • Major Pharmaceutical Preparations Industry
PCRX
Clinical Study
HUTCHMED to Showcase Innovative Clinical Findings at the 2025 ESMO Asia Congress and ASH Annual Meeting

In a notable advancement for the oncology and hematology communities, HUTCHMED (China) Limited has announced that it will unveil new and updated clinical data at two prominent international meetings the European Society for Medical Oncology (ESMO) Asia Congress 2025 and the American Society of Hematology (ASH) Annual Meeting. These presentations, schedule...

Nov 27, 2025 • Major Pharmaceutical Preparations Industry
HCM
Business Update
Unveiling New Horizons in Cancer Therapy The Transformative Potential of Sonrotoclax and TEVIMBRA in Modern Oncolog...

Biopharmaceutical advances continue to transform the landscape of cancer treatment, offering new hope where traditional therapies have fallen short. In this article, we delve into the latest developments surrounding BeOne Medicines Ltd. s promising oncological agents, sonrotoclax and TEVIMBRA, two compounds set to redefine treatment protocols for various ...

Nov 27, 2025 • Major Pharmaceutical Preparations Industry
ONC
Announcement
Navigating Legal and Financial Quagmires The Case of Perrigo Company Plc Amidst Competitive Pressures

The pharmaceutical industry is characterized by rapid fluctuations in revenue and intense competition, often pitting companies against one another in the race for market dominance. The recent performance of Perrigo Company Plc (NYSE: PRGO) provides a case study in the complexities of maintaining profitability amid industry challenges. This article examine...

Nov 24, 2025 • Major Pharmaceutical Preparations Industry
PRGO
Announcement
Clearmind Medicine Unwavering Progress in the Quest for Alcohol Use Disorder Treatments Amidst Financial Challenges

In a noteworthy development within the biotech landscape, Clearmind Medicine Inc. (Nasdaq: CMND), a Vancouver-based company dedicated to pioneering novel therapeutics for under-treated health issues, has received unanimous endorsement from its independent Data and Safety Monitoring Board (DSMB) to continue its Phase I/IIa clinical trial for CMND-100. This...

Nov 24, 2025 • Major Pharmaceutical Preparations Industry
CMND
Business Update
s at the ESMO 2025 Congress in Berlin, where it unveiled promising new data from two pivotal Phase 3 trials, RATIONAL...

BeOne Medicines: Pioneering Advances in Oncology with Promising Data from ASH 2025 and ESMO 2025 SAN CARLOS, California BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) is poised to maintain its status as a leader in innovative oncology solutions with significant advancements showcased at major medical conferences, including the American S...

Nov 20, 2025 • Major Pharmaceutical Preparations Industry
ONC
Business Update
Compass Pathways Expands Influence in Mental Health Innovation with Upcoming Investor Conferences and Strategic Colla...

In December 2025, Compass Pathways plc (Nasdaq: CMPS), a biotechnology firm focused on mental health solutions, has scheduled participation in two notable investor conferences aimed at enhancing its visibility and attracting potential investors. The company will engage in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Fl...

Nov 20, 2025 • Major Pharmaceutical Preparations Industry
CMPS
Product Service News
Libtayo (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneo...

Pioneering Advancements in Immunotherapy: Libtayo and Dupixent Set New Benchmarks in Cancer and Chronic Illness TreatmentsIn a significant stride for modern oncology and immunological treatments, the European Union has approved Libtayo (cemiplimab) as the first and only immunotherapy for the adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) ...

Nov 19, 2025 • Major Pharmaceutical Preparations Industry
REGN
Business Update
Evolving HER2-Positive Cancer Treatments BeOne Medicines’ Breakthrough Phase-3 Results for ZIIHERA and Son...

In a significant advancement for oncology, BeOne Medicines Ltd., recognized for its innovative approaches in cancer treatment, has recently announced compelling results from its Phase-3 clinical trials. These results underscore the potential of ZIIHERA as the preferred treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcin...

Nov 19, 2025 • Major Pharmaceutical Preparations Industry
ONC
Announcement
Legal Turbulence in the Biopharmaceutical Sector Analyzing MoonLake Immunotherapeutics Recent Performance and Invest...

The biopharmaceutical industry is characterized by rapid innovation and intense competition, which can have significant implications for investors. A recent class action lawsuit filed against MoonLake Immunotherapeutics has drawn attention to the company s underperformance compared to its peers and raises essential questions about corporate governance and...

Nov 18, 2025 • Major Pharmaceutical Preparations Industry
MLTX
Product Service News
Navigating the Therapeutic Frontier Kura Oncologys KOMZIFTI Approval Amidst Competitive Pressures

In recent developments within the pharmaceutical landscape, Kura Oncology and Kyowa Kirin s announcement of the FDA approval for KOMZIFTI (ziftomenib) marks a transformative moment for patients grappling with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This approval not only represents the first and only once-daily targeted therapy f...

Nov 14, 2025 • Major Pharmaceutical Preparations Industry
KURA
Product Service News
Advancing the Future of Cell Therapy Legend Biotechs New Facility and Inaugural ESG Report

In the rapidly evolving field of cell therapy, Legend Biotech Corporation stands out as a leader in innovation and sustainability. This article reviews the recent endeavors undertaken by Legend Biotech, including the official opening of its state-of-the-art cell therapy research and development facility in Philadelphia and the publication of its inaugural...

Nov 14, 2025 • Major Pharmaceutical Preparations Industry
LEGN
Clinical Study
Breakthrough in Autoimmune Therapy Cartesian Therapeutics Shines with Descartes-08 in SLE and Myasthenia Gravis Trials

A New Dawn for Autoimmune Diseases: Cartesian Therapeutics Descartes-08 Shows Promising Results in SLE and Myasthenia GravisIn a landscape where autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis pose significant challenges to patients and clinicians alike, Cartesian Therapeutics is making impressive strides with its mR...

Nov 14, 2025 • Major Pharmaceutical Preparations Industry
RNAC
Clinical Study
Promising Advances in mCRPC Treatment Insights from ORIC-944 Phase 1b Trials

: The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to challenge clinicians due to inherent and acquired therapeutic resistance. In recent developments, ORIC Pharmaceuticals has reported promising results from its ongoing Phase 1b clinical trial evaluating ORIC-944, an innovative, experimental therapy designed...

Nov 14, 2025 • Major Pharmaceutical Preparations Industry
ORIC
Clinical Study
Eupraxia Pharmaceuticals Shows Promising Long-Term Efficacy in EoE Treatment and Achieves Industry-Leading Leverage R...

Eupraxia Pharmaceuticals Progress in EoE Treatment: Eupraxia Pharmaceuticals has reported encouraging 52-week follow-up results from their RESOLVE clinical trial, focusing on their investigational therapy, EP-104GI, for Eosinophilic Esophagitis (EoE). This chronic immune system disease, characterized by an overabundance of eosinophils in the esophageal l...

Nov 14, 2025 • Major Pharmaceutical Preparations Industry
EPRX
Announcement
Clearmind Medicine Pioneers AUD Treatment Expansion Innovative Trials Surge Ahead Despite Market Fluctuati...

In a significant advancement for the future of Alcohol Use Disorder (AUD) treatment, Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) announced it has received final approval to expand its innovative Phase 1/2a clinical trial at the prestigious Hadassah Medical Center in Jerusalem, Israel. The company, known for pioneering psychedelic-derived therapeutic...

Nov 13, 2025 • Major Pharmaceutical Preparations Industry
CMND
Clinical Study
Safety and Efficacy Evaluation of Roflumilast Cream 0.05% in Infants with Atopic Dermatitis Insights from the INTEGUM...

: Arcutis Biotherapeutics, Inc. has completed enrollment for its Phase 2 clinical trial, INTEGUMENT-INFANT, assessing the safety and efficacy of ZORYVE (roflumilast) cream 0.05% in infants diagnosed with atopic dermatitis (AD). This study is part of Arcutis broader clinical development program for roflumilast, which has shown promise in other dermatologi...

Nov 13, 2025 • Major Pharmaceutical Preparations Industry
ARQT
Contract
Adagene and Third Arc Bio Forge Pioneering Alliance A New Era for Targeted Cancer Therapies

In a strategic move that signals the ongoing evolution of cancer therapeutics, Adagene Inc. has announced a licensing agreement with Third Arc Bio, Inc. to develop two masked CD3 T cell engagers utilizing Adagene’s proprietary SAFEbody technology. The agreement, unveiled on November 13, 2025, marks a significant milestone not just for the companies invo...

Nov 13, 2025 • Major Pharmaceutical Preparations Industry
ADAG
Clinical Study
for the Regeneron Breaks New Ground at ASH Innovative Hematology Therapies and Strategic Weight Management...

Regeneron Advances Therapeutic Frontier at ASH: Novel Data in Multiple Myeloma, Lymphoma, and Paroxysmal Nocturnal Hemoglobinuria Unveiled Regeneron Pharmaceuticals recently showcased significant progress in its hematology pipeline at the American Society of Hematology (ASH) meeting, highlighting several groundbreaking studies. With a strong focus on inno...

Nov 13, 2025 • Major Pharmaceutical Preparations Industry
REGN
Clinical Study
Opus Genetics Doses First Participant in Phase 1/2 Clinical Trial for Best Disease Gene Therapy,

In a pioneering move in the field of ophthalmic gene therapy, Opus Genetics has achieved a significant milestone by dosing the first participant in its OPGx-BEST1 Phase 1/2 clinical trial aimed at treating Best Disease, a rare inherited retinal disorder. This landmark occasion not only sets the stage for potential breakthroughs in the treatment of this de...

Nov 13, 2025 • Major Pharmaceutical Preparations Industry
IRD
Business Update
Navigating New Neuroscapes Aldeyra Therapeutics Expands RASP Platform Beyond Boundaries,

Unlocking New Frontiers: Aldeyra Therapeutics Expands RASP Platform to Address Central Nervous System Diseases In a groundbreaking announcement during a recent Research and Development webcast, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) signaled a pivotal expansion of its Reactive Aldehyde Species (RASP) platform, now extending its innovative approaches to...

Nov 13, 2025 • Major Pharmaceutical Preparations Industry
ALDX
Business Update
Vistagen’s Neuroscientific Surge Financial Acumen, Anxiety Insights, and Pioneering Pain Patent,

: Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, continues to advance its neuroscience initiatives. With a focus on using nose-to-brain neurocircuitry, the company is developing intranasal product candidates known as pherines, targeting neurological and psychiatric conditions. Vistagen will disclose its fiscal year 2026 second...

Nov 10, 2025 • Major Pharmaceutical Preparations Industry
VTGN
Clinical Study
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-S...

AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biotechnology company centered on pioneering immunology therapeutics, the much-anticipated results from its Phase 2 trial for rosnilimab in th...

Nov 10, 2025 • Major Pharmaceutical Preparations Industry
ANAB
Business Update
AN2 Therapeutics Partners with GSK to Combat Tuberculosis with Innovative Boron-Based Therapies

In a significant advancement in the fight against tuberculosis (TB), AN2 Therapeutics, Inc., a pioneering biopharmaceutical company based in Menlo Park, California, has announced a research collaboration with the global biopharmaceutical giant GlaxoSmithKline (GSK). This partnership aims to develop novel therapies utilizing boron-based leucyl-tRNA synthet...

Nov 10, 2025 • Major Pharmaceutical Preparations Industry
ANTX
Clinical Study
Pre-Clinical Insights from IO Biotech Advancements in Therapeutic Cancer Vaccine Candidates Presented at SITC 2025

At the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), IO Biotech presented compelling pre-clinical data on its additional therapeutic cancer vaccine candidates. This research highlights the company s commitment to advancing immunotherapeutic approaches in oncology. Alongside this, recent market performance indicators suggest a posi...

Nov 7, 2025 • Major Pharmaceutical Preparations Industry
IOBT
Clinical Study
The field of immunotherapy is witnessing a paradigm shift with groundbreaking innovations design...

Expanding the Horizons of Immunotherapy: Advances in Werewolf Therapeutics’ PREDATOR and INDUKINE Platforms The field of immunotherapy is witnessing a paradigm shift with groundbreaking innovations designed to enhance therapeutic efficacy while minimizing adverse effects. Werewolf Therapeutics, a prominent biotech firm, unveiled promising data from its...

Nov 7, 2025 • Major Pharmaceutical Preparations Industry
HOWL
Clinical Study
Advancing Immunotherapy Frontiers Elicio Therapeutics Promising Progress in Targeting mKRAS Mutations

: This article delves into the recent developments and promising advancements announced by Elicio Therapeutics, a clinical-stage biotechnology leader in cancer immunotherapy. By examining the emerging data from their ongoing Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on ELI-004, we assess their impact on pancreatic ductal adenocarcinoma...

Nov 7, 2025 • Major Pharmaceutical Preparations Industry
ELTX
Clinical Study
Nurix Therapeutics Advances Immunotherapy and Targeted Therapy with Promising Data from NX-1607 and Novel Degraders

Nurix Therapeutics has recently made significant strides in the field of oncology and immunology with their pioneering research and development programs. Building upon a series of compelling studies and validatory preclinical data, the company has showcased the promising potential of their investigational agents NX-1607 and the lead Bruton s tyrosine kina...

Nov 7, 2025 • Major Pharmaceutical Preparations Industry
NRIX
Business Update
Advancements in Autoimmune Hepatitis Treatment Kezar Life Sciences to Present Phase 2a PORTOLA Trial Data at AASLD 2025

: Kezar Life Sciences, a clinical-stage biotechnology company, is poised to present significant data from its Phase 2a PORTOLA clinical trial evaluating the efficacy of zotomipzomib in treating autoimmune hepatitis (AIH) at The Liver Meeting 2025 organized by the American Association for the Study of Liver Disease. The upcoming presentations, scheduled f...

Nov 7, 2025 • Major Pharmaceutical Preparations Industry
KZR

Decision Framework & Data Access

Power onboarding, benchmarking, and quantitative analysis with institutional-grade datasets structured for direct integration into financial models and risk frameworks.

  • Industry benchmarking datasets (valuation, growth, profitability)
  • Designed for quant models, AML/KYC validation & onboarding workflows
  • Consistent time-series structure (Quarterly, TTM, Annual)
  • Coverage across 100+ industries and 20+ years of history
CSV - SFTP - REST API - Daily Updates - Integration-ready for Python, R & BI tools
Get the full CSIMarket dataset: Subscribe API License